Latest Market News

Page 1730 of 1826
Mastermyne Group Limited reported a 14% rise in EBITDA to $4.1 million for FY25 Q2, even as revenue fell 10% due to operational disruptions at Anglo American’s Grosvenor mine. The company secured key contract extensions and maintained a strong cash position, positioning itself for growth amid sector uncertainties.
Victor Sage
Victor Sage
31 Jan 2025
Patriot Lithium Limited has made significant strides in acquiring and exploring copper projects in Zambia while navigating complex negotiations for its key Gorman Lithium Project in Canada.
Maxwell Dee
Maxwell Dee
31 Jan 2025
Pacific Current Group reports a 6.1% increase in total Funds Under Management to A$30 billion as of December 31, 2024, despite a decline in USD-denominated assets and exits from two boutique managers.
Claire Turing
Claire Turing
31 Jan 2025
Careteq Limited reports solid progress in integrating its Embedded Health Solutions with HMR Referrals, alongside a 14% revenue increase and improved cash flow in Q2 FY25.
Victor Sage
Victor Sage
31 Jan 2025
Prophecy International has inked a three-year global reseller agreement with US SIEM leader Securonix, aiming to generate over $1 million in new annual recurring revenue within the first year.
Sophie Babbage
Sophie Babbage
31 Jan 2025
Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.
Ada Torres
Ada Torres
31 Jan 2025
PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for Autosomal Dominant Optic Atrophy, marking a pivotal step in developing a treatment for this currently untreatable blinding disease.
Ada Torres
Ada Torres
31 Jan 2025
Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.
Ada Torres
Ada Torres
31 Jan 2025
Botanix Pharmaceuticals has initiated the commercial rollout of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, with first prescriptions dispensed and a fully trained sales force deployed. The company anticipates meaningful revenue growth starting in the first quarter of 2025, backed by strong payer contracts and a robust cash position.
Victor Sage
Victor Sage
31 Jan 2025
QEM Limited has marked significant progress in its Julia Creek Vanadium and Energy Project, securing key government approvals and raising $2.76 million to advance development and environmental studies.
Maxwell Dee
Maxwell Dee
31 Jan 2025
TerraCom Limited reported resilient coal sales of 1.6 million tonnes for the December quarter despite weather disruptions, while advancing its Moorlands Thermal Coal Project and maintaining a fully franked dividend.
Maxwell Dee
Maxwell Dee
31 Jan 2025
Ecofibre Limited reports a mixed financial performance for Q2 2025, highlighting significant debt reduction efforts and strategic restructuring to return to positive cash flows.
Victor Sage
Victor Sage
31 Jan 2025